2023.

• Mar.27.2023 R & D

  ONO Receives Supplemental Approval of Opdivo in Combination with Chemotherapy for Neoadjuvant Treatment of Non-Small Cell Lung Cancer in Japan

• Mar.27.2023 Sustainability

  ONO Sets New Targets of Medium- to Long-Term Environment Vision
  - Toward Realization of Medium- to Long-Term Environment Vision, ECO VISION 2050 -

• Mar.23.2023 R & D

  Opdivo® Intravenous Infusion Approved in South Korea for the First-line Treatment of Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma in Two Combination Treatments of Opdivo + Yervoy and Opdivo + Chemotherapy

• Mar.23.2023 Licensing

  Ono Enters into a Drug Discovery Collaboration Agreement with Macomics to Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer

• Mar.23.2023 Licensing

  Ono Enters into a Drug Discovery Collaboration Agreement with MOLCURE to Discover and Develop Innovative Antibody Drugs for Multiple Targets Utilizing MOLCURE’s AI-driven Platform Technology

• Mar.22.2023 R & D

  Opdivo® Intravenous Infusion Approved in Combination with Yervoy in Taiwan for the Treatment of Hepatocellular Carcinoma Previously Treated with Sorafenib

• Mar.15.2023 Licensing

  Ono Enters into a Drug Discovery Collaboration Agreement with PeptiDream to Discover and Develop Macrocyclic Constrained Peptide Therapeutics

• Mar.01.2023 R & D

  U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

• Feb.28.2023 R & D

  ONO Submits Supplemental Application for Approval of Opdivo® in Japan to Expand its Use for the Treatment of Malignant Mesothelioma (Excluding Malignant Pleural Mesothelioma)

• Feb.22.2023 Licensing

  Ono Enters into a Collaboration and Option Agreement with Cue Biopharma for CUE-401, a Bispecific Protein

• Feb.22.2023 R & D

  Opdivo® Intravenous Infusion Approved for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Combination with Chemotherapy in Taiwan

• Feb.20.2023 R & D

  Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial

• Feb.17.2023 R & D

  Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

• Feb.15.2023 Corporate

  Support for Relief Efforts in the Earthquake in Turkey and Syria

• Feb.08.2023 Sustainability

  Release of Video titled “Surviving Cancer” that Conveys the Thoughts of Cancer Patients

• Jan.31.2023 Management / Finance

  Announcement on Financial Results for FY2022 3Q

• Jan.31.2023 Corporate

  Notice Concerning the Establishment of “Ono Pharma Oncology, Immunology, Neurology Research Foundation,” a General Incorporated Foundation

• Jan.25.2023 Licensing

  Ono Acquires Multiple Research-Stage Oncology Programs from KSQ Therapeutics

• Jan.16.2023 Corporate

  Notice concerning the Start of Joint Transportation in the Domestic Distribution of Prescription Pharmaceuticals

• Jan.13.2023 Licensing

  Ono Enters an Option and Research Collaboration Agreement with Monash University to Discover Anti-GPCR Antibodies in the Autoimmune and Inflammatory Diseases

• Jan.13.2023 Corporate

  Notice concerning Certification as a “DX Certified Business Operator” Stipulated by the Ministry of Economy, Trade and Industry

• Jan.10.2023 Products

  Revision of Electronic Package Insert of Forxiga, a Selective SGLT2 inhibitor, related to Indication of Chronic Heart Failure